Abstracts Archive - Page 118 of 2425 - ACR Meeting Abstracts

Abstract Number: 1494 • ACR Convergence 2024
Trajectories of Disease Evolution upon Treatment Initiation in Systemic Lupus Erythematosus: Pooled Results from Three Randomized Clinical Trials of Belimumab
Ioannis Parodis¹, Julius Lindblom², Alexandre Tsoi³, Dionysis Nikolopoulos⁴ and Lorenzo Beretta⁵, ¹Karolinska Institutet, Karolinska University Hospital; Örebro University, Solna, Sweden, ²Karolinska Institutet, Stockholm, Sweden, ³Karolinska Institute, Stockholm, Sweden, ⁴Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, ⁵Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di MIlano, Milan, Milan, Italy
Background/Purpose: The efficacy of belimumab in treating SLE has been demonstrated in several phase 3 randomized clinical trials (RCTs). These trials showed belimumab efficacy on…
Abstract Number: 1517 • ACR Convergence 2024
Diagnostic Performance of Anti-dsDNA Antibodies in Pleural, Ascitic and Pericardial Fluid for Lupus Serositis: Experience of a Tertiary Center in Mexico
Marlon Sandino-Bermúdez¹, Erik Cimé-Aké², Jonathan Campos-Guzmán³, Eduardo Briones-García⁴, Emilio G. Lazarini², Carlos Núñez-Álvarez⁵ and Hilda Fragoso-Loyo², ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Distrito Federal, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Immunology and Rheumatology Department, Mexico City, Mexico, ³Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁴Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Immunology and Rheumatology Department., Ciudad de México, Distrito Federal, Mexico, ⁵Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, CDMX, Mexico, Mexico, Mexico
Background/Purpose: The diagnosis of serositis in systemic lupus erythematosus (SLE) relies on combining clinical and serological data, alongside imaging studies. The aim of this study…
Abstract Number: 1390 • ACR Convergence 2024
One-year Real World Evidence Outcomes from the Cohort RADIUS (Real-world Analysis of Upadacitinib in Rheumatoid Arthritis Patients for Improved Understanding and Safety)
Luis Gomez-Lechon Quiros¹, José Miguel Sequí-Sabater², Amalia Rueda³, Costas Torrijo Nerea⁴, Carlos Valera-Ribera⁵, Juan Miguel López-Gómez⁶ and Antonio Alvarez-Cienfuegos⁷, ¹Hospital Francesc de Borja, Valéncia, Spain, ²La Ribera University Hospital, Rheumatology Department, Gandía, Comunidad Valenciana, Spain, ³Hospital General de Valencia, VALENCIA, Comunidad Valenciana, Spain, ⁴Generalitat valenciana, Valencia, Spain, ⁵Hospital Doctor Peset, Valéncia, Comunidad Valenciana, Spain, ⁶Conselleria de Sanitat/Hospital Universitario de Elda, Elda, Comunidad Valenciana, Spain, ⁷Conselleria de Sanitat/Hospital de la Vega Baja, Orihuela, Comunidad Valenciana, Spain
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic inflammatory disease that affects the joints and other parts of the musculoskeletal system. Early diagnosis and initiation of…
Abstract Number: 1030 • ACR Convergence 2024
Diversity in Axial Spondyloarthritis Drug Trials: Examining Enrollment by Sex, Race, Ethnicity and Geographic Region
Mathieu Choufani¹, Wissam Ghusn² and Joerg Ermann³, ¹Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, ²Department of Internal Medicine, Boston Medical Center, Boston, MA, ³Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: While axial spondyloarthritis (AxSpA) was historically perceived as a "white man's disease", it is now appreciated as a condition that can affect individuals of…
Abstract Number: 1262 • ACR Convergence 2024
The Relationship Between Child Opportunity Index and Burden of Pediatric Systemic Lupus Erythematosus
Ayah Eltoum¹, Livie Timmerman², Melissa Mannion¹ and Emily Smitherman¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Gardendale, AL
Background/Purpose: Outcomes for systemic lupus erythematosus are known to be associated with sociodemographic indicators. The Child Opportunity Index (COI) is a well-validated measure of neighborhood…
Abstract Number: 1518 • ACR Convergence 2024
Predictive Value of Chronic Histologic Changes in Lupus Nephritis
Maria Cuellar-Gutierrez¹, Jaime Flores Gouyonnet¹, Gabriel Figueroa-Parra², Marta Casal Moura¹, Fernando C. Fervenza¹, Andrew C. Hanson³, Cynthia Crowson¹, Sanjeev Sethi¹ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ³Mayo Clinic, Rochester
Background/Purpose: We aimed to assess the predictive value of the individual components of the NIH chronicity score and the Mayo Clinic Chronicity Score (MCCS) in…
Abstract Number: 1400 • ACR Convergence 2024
Disease Modifying Anti-rheumatic Drug Use and Association with Survival in Patients with Rheumatoid Arthritis and Newly Diagnosed Lung Cancer
Varun Nandakumar¹, Aaron Baraff², Alexander Peterson², Nicholas Smith³, Jennifer Barton⁴, Ann O'Hare², Christopher Li⁵, Noel Weiss³ and Namrata Singh⁶, ¹AIIMS, New Delhi, Delhi, India, ²VA PUGET SOUND SEATTLE, Seattle, WA, ³University of Washington, Seattle, WA, ⁴VA Portland Health Care System/OHSU, Portland, OR, ⁵University of Washington, Seattle, ⁶University of Washington, Bellevue, WA
Background/Purpose: Despite the significant therapeutic benefits of various disease modifying anti-rheumatic drugs (DMARDs) in RA, concerns remain regarding their safety, particularly their potential impact on…
Abstract Number: 1040 • ACR Convergence 2024
Clinic Personnel Perceptions Were Favorable for the Implementation of a Patient Decision-Aid for a Diverse Systemic Lupus Erythematosus Population: A Study in 15 U.S. Rheumatology Clinics
Jasvinder Singh¹, Larry Hearld², Walter Chatham³, Sonali Narain⁴, Narender Annapureddy⁵, Diane Kamen⁶, Kimberly Trotter⁷, vikas Majithia⁸, Cathy Lee Ching⁹, Zineb Aouhab¹⁰, Swamy Venuturupalli¹¹, Daniel Wallace¹², rosalind Ramsey-Goldman¹³, Alfred Kim¹⁴, Maureen McMahon¹⁵, S. Sam Lim¹⁶, Kalpana Bhairavarasu¹⁷, Alexa Meara¹⁸ and Kenneth Kalunian¹⁹, ¹Baylor College of Medicine, Birmingham, AL, ²University of Alabama at Birmingham (UAB), Birmingham, AL, ³University of Nevada, Las Vegas, Las Vegas, NV, ⁴Northwell Health, Great Neck, NY, ⁵Vanderbilt University Medical Center, Nashville, TN, ⁶Medical University of South Carolina, Charleston, SC, ⁷University of Chicago, Chicago, IL, ⁸University of Missisippi Medical Center (UMC), Jackson, MS, ⁹UMMC, Jackson, MS, ¹⁰Loyola University Medical Center, Oak Brook, IL, ¹¹Attune Health, Beverly Hills, CA, ¹²Cedars Sinai Medical Center, Studio City, CA, ¹³Northwestern University, Chicago, IL, ¹⁴Washington University School of Medicine, Division of Rheumatology, Department of Medicine, St Louis, MO, ¹⁵UCLA David Geffen School of Medicine, Los Angeles, CA, ¹⁶Emory University, Atlanta, GA, ¹⁷Baylor College of Medicine, Sugar Land, TX, ¹⁸The Ohio State University Wexner Medical Center, COLUMBUS, OH, ¹⁹University of California San Diego, La Jolla, CA
Background/Purpose: To understand clinic personnel feedback regarding the implementation of a self-administered patient decision-aid (PtDA) for lupus in regular, outpatient rheumatology clinics.Methods: We provided self-administered…
Abstract Number: 1054 • ACR Convergence 2024
Utilization of Rehabilitation Services in Patients with Common Rheumatic Conditions: A Systematic Review
Keri Geinosky¹, Joel Thompson², Joshua Torrey³ and Louise Thoma⁴, ¹University of North Carolina at Chapel Hill, Chapel Hill, ²university of north carolina - chapel hill, Cary, NC, ³UNC Chapel Hill, Westmoreland, NH, ⁴University of North Carolina, Chapel Hill, NC
Background/Purpose: Rehabilitation services, such as physical therapy (PT) and occupational therapy (OT), are recommended in the care of inflammatory arthritis and other rheumatic conditions. However, the…
Abstract Number: 1522 • ACR Convergence 2024
Impact of Thrombocytopenia on In-hospital Mortality and Healthcare Resource Utilization in Patients with Systemic Lupus Erythematosus: An Analysis of the National Inpatient Sample Database 2020
Soziema Salia¹, Ufuoma Mamoh², Gilava Hedayati², Joseph Atarere³, Raymond Wadie⁴, Boniface Mensah³, Joan Morny⁵ and Indira Acharya⁶, ¹MedStar Union Memorial Hospital, Towson, MD, ²Medstar Union Memorial Hospital, Baltimore, MD, ³Department of Internal Medicine, MedStar Union Memorial Hospital, Baltimore, MD, ⁴Department of Internal Medicine, Cayuga Medical Center, Ithaca, NY, ⁵Piedmont Athens Regional Medical Center, Athens, GA, ⁶Medstar Internal Medicine Residency Program, Baltimore, MD
Background/Purpose: Thrombocytopenia is associated with Systemic Lupus Erythematosus (SLE) and occurs at various stages of the disease. It is reported in an estimated 10% to 40% of…
Abstract Number: 1272 • ACR Convergence 2024
Angiopoietin-2 and Soluble Tumor Necrosis Factor Receptor Type II Are Elevated in Treatment Naïve JDM Plasma and Associate with Increased Muscle Disease Activity and Decreased Nailfold Capillary Density
Sophia Matossian¹, Julie Sturza², Megan Mattichak¹, William Brodie¹, Christine Goudsmit¹, Nicholas McClellan¹, J. Michelle Kahlenberg¹, Pei-Suen Tsou¹ and Jessica Turnier³, ¹University of Michigan, Ann Arbor, MI, ²Michigan Medicine Biostatistics and Data Management, Ann Arbor, MI, ³University of Michigan, Saline, MI
Background/Purpose: Juvenile Dermatomyositis (JDM) is an autoimmune disease characterized by vasculopathy in skin and muscle, where endothelial cell (EC) dysfunction is thought to contribute to…
Abstract Number: 1527 • ACR Convergence 2024
Comparative Harms in Patients with Systemic Lupus Erythematosus Treated with Anifrolumab or Belimumab: A Multicenter Cohort Study Using the TriNetX Research Network
Hsin-Hua Chen, Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China)

Background/Purpose: Belimumab and anifrolumab, biologic therapies, have shown to improve systemic lupus erythematosus (SLE) outcomes in clinical trials, but there is a lack of real-world…
Abstract Number: 1403 • ACR Convergence 2024
Development, Validation and Clinical Use of Health-Related Behaviour Health Fitness Questionnaire (HR-BHF) in Indian (Asian) Subjects Attending a Community Rheumatology Center
MANJIT SALUJA¹ and ARVIND CHOPRA², ¹CENTER FOR RHEUMATIC DISESAES, Pune, Maharashtra, India, ²CENTER FOR RHEUMATIC DISEASES, Pune, Maharashtra, India
Background/Purpose: Our patients often express concerns related to ‘wellbeing’ that are not routinely attended during standard care (including QOL). Alternatively, these concerns are important components…
Abstract Number: 1501 • ACR Convergence 2024
Retrospective Cohort Study Identifying Pulmonary Complications in a Cohort of Patients with Systemic Lupus Erythematosus
Jessica Johnson¹, Chao Zhang² and Emily Littlejohn³, ¹Cleveland Clinic Lerner College of Medicine, Cleveland, OH, ²Cleveland Clinic, Cleveland Heights, OH, ³Cleveland Clinic, Cleveland, OH
Background/Purpose: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with multi organ involvement. One of the most common manifestations is pulmonary disease with a…
Abstract Number: 1531 • ACR Convergence 2024
Prospective mRNA SARS-CoV-2 Additional Vaccination in Systemic Autoimmune Disease Patients on Immunosuppressive Medications in a Randomized Controlled Trial
Meggan Mackay¹, Catriona Wagner², Ashley Pinckney³, Jeffrey Cohen⁴, Zachary Wallace⁵, Arezou Khosroshahi⁶, Jeffrey Sparks⁷, Sandra Lord⁸, Amit Saxena⁹, Roberto Caricchio¹⁰, Alfred Kim¹¹, Diane Kamen¹², Fotios Koumpouras¹³, Anca Askanase¹⁴, Kenneth Smith¹⁵, Joel Guthridge¹⁵, Susan Macwana¹⁶, Sean McCarthy¹⁷, Matthew Sherman¹⁸, Sanaz Daneshfar Hamrah¹⁹, Maria Veri¹⁹, Kate York²⁰, Sarah Walker²¹, Sandeep Narpala²², Robin Carroll²², Bob Lin²², Leonid Serebryanny²², Adrian McDermott²³, William Barry²¹, Ellen Goldmuntz²⁴, James McNamara²⁵, Sara Tedeschi²⁶, Amit Bar-Or²⁷, Dinesh Khanna²⁸, ACV01 Clinical Study Team¹⁵ and Judith James¹⁵, ¹Feinstein Institutes for Medical Research, Manhasset, NY, ²Oklahoma Medical Research Foundation, Santa Cruz, CA, ³Rho, St Louis Park, NC, ⁴Neurologic Institute, Cleveland Clinic, Cleveland, OH, USA, Cleveland, OH, ⁵Massachusetts General Hospital, Newton, MA, ⁶Emory University, Atlanta, GA, ⁷Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA, ⁸Center for Interventional Immunology, Benaroya Research Institute, Seattle, WA., Seattle, WA, ⁹NYU School of Medicine, New York, NY, ¹⁰University of Massachusetts Chan Medical School, Worcester, MA, ¹¹Washington University School of Medicine, Division of Rheumatology, Department of Medicine, St Louis, MO, ¹²Medical University of South Carolina, Charleston, SC, ¹³Yale School of Medicine, New Haven, CT, ¹⁴Columbia University Medical Center, New York, NY, ¹⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁶Oklahoma Medical Research Foundation, Oklahoma City, ¹⁷DAIT/NIAID/NIH, Rockville, MD, ¹⁸DAIT/NIAID/NIH, Washington, DC, ¹⁹Division of Allergy, Immunology, and Transplantation, NIH/NIAID, Bethesda, MD, USA., Bethesda, MD, ²⁰Rho Federal Systems Division, Durham, NC, USA., Durham, NC, ²¹Rho, Durham, NC, ²²Vaccine Research Center, NIH/NIAID, Bethesda, MD, USA, Bethesda, MD, ²³Vaccine Research Center, NIH/NIAID, Bethesda, MD, ²⁴NIAID/ NIH, Washington, DC, ²⁵NIH, Bethesda, MD, ²⁶Brigham and Women's Hospital, Boston, MA, ²⁷Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA, Philadelphia, PA, ²⁸Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI
Background/Purpose: Autoimmune disease patients treated with mycophenolate mofetil/mycophenolic acid (MMF/MPA), methotrexate (MTX), or B cell-depleting therapies (BCDT) exhibit reduced humoral responses following primary two-dose COVID-19…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].